Ozurdex launched in China for RVO

Ozurdex launched in China for RVO

Colin Kerr

Published: Tuesday, May 1, 2018

Allergan has announced the launch of Ozurdex (dexamethasone intravitreal implant 0.7mg) in China for the treatment of adult patients with macular oedema secondary to retinal vein occlusion (RVO). Ozurdex is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular oedema following BRVO and CRVO. “Providing millions of RVO patients access to Ozurdex is a significant step towards preventing blindness and meeting a critical unmet need in China,” said Marc Princen, Allergan International President. http://www.allergan.com/

Latest Articles

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Picture This: Photo Contest Winners

ESCRS 2025 Refractive and Cataract Photo Contest winners.

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Supplement: ESCRS Clinical Trends Series: Presbyopia

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

New Award to Encourage Research into Sustainable Practices

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.